The landscape surrounding medicinal cannabis, particularly cannabidiol (CBD) oil, in Australia has undergone a significant transformation, prompting Australian doctors to re-evaluate their therapeutic approaches and patient counselling. For years, skepticism prevailed due to a lack of robust clinical evidence and historical stigma. However, with the Therapeutic Goods Administration (TGA) down-scheduling of low-dose CBD to Schedule […]